| dc.contributor.author | Dréan, A | |
| dc.contributor.author | Lord, CJ | |
| dc.contributor.author | Ashworth, A | |
| dc.date.accessioned | 2017-03-27T09:56:11Z | |
| dc.date.issued | 2016-12-01 | |
| dc.identifier.citation | Critical reviews in oncology/hematology, 2016, 108 pp. 73 - 85 | |
| dc.identifier.issn | 1040-8428 | |
| dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/532 | |
| dc.identifier.eissn | 1879-0461 | |
| dc.identifier.doi | 10.1016/j.critrevonc.2016.10.010 | |
| dc.description.abstract | In 2014, olaparib (Lynparza) became the first PARP (Poly(ADP-ribose) polymerase) inhibitor to be approved for the treatment of cancer. When used as single agents, PARP inhibitors can selectively target tumour cells with BRCA1 or BRCA2 tumour suppressor gene mutations through synthetic lethality. However, PARP inhibition also shows considerable promise when used together with other therapeutic agents. Here, we summarise both the pre-clinical and clinical evidence for the utility of such combinations and discuss the future prospects and challenges for PARP inhibitor combinatorial therapies. | |
| dc.format | Print-Electronic | |
| dc.format.extent | 73 - 85 | |
| dc.language | eng | |
| dc.language.iso | eng | |
| dc.publisher | ELSEVIER SCIENCE INC | |
| dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
| dc.subject | Animals | |
| dc.subject | Humans | |
| dc.subject | Neoplasms | |
| dc.subject | Poly(ADP-ribose) Polymerases | |
| dc.subject | Drug Combinations | |
| dc.subject | Immunotherapy | |
| dc.subject | Poly(ADP-ribose) Polymerase Inhibitors | |
| dc.title | PARP inhibitor combination therapy. | |
| dc.type | Journal Article | |
| dcterms.dateAccepted | 2016-10-26 | |
| rioxxterms.versionofrecord | 10.1016/j.critrevonc.2016.10.010 | |
| rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
| rioxxterms.licenseref.startdate | 2016-12 | |
| rioxxterms.type | Journal Article/Review | |
| dc.relation.isPartOf | Critical reviews in oncology/hematology | |
| pubs.notes | No embargo | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Gene Function | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Gene Function | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Gene Function | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Gene Function | |
| pubs.publication-status | Published | |
| pubs.volume | 108 | |
| pubs.embargo.terms | No embargo | |
| icr.researchteam | Gene Function | |
| dc.contributor.icrauthor | Drean, Amy | |
| dc.contributor.icrauthor | Lord, Christopher | |
